Tandem high-dose chemotherapy with autologous peripheral hematopoietic progenitor cell rescue as consolidation therapy for patients with high-risk Ewing Family Tumors

Michael J. Burke, David O Walterhouse*, David A. Jacobsohn, Reggie E Duerst, Morris Kletzel

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

24 Scopus citations

Abstract

The role of tandem high-dose chemotherapy (HDC) with autologous peripheral hematopoietic progenitor cell rescue (APHPCR) in patients with Ewing Family Tumors (EFT) is controversial. We initiated treatment for eight consecutive patients with high-risk EFT with HDC and APHPCR from 1992 to 2003. There were no treatment related deaths. Four patients remain in complete remission, including three who did not undergo local therapy to bone at either the primary or metastatic sites. Our experience has shown that treatment of EFT patients with tandem HDC with APHPCR may benefit a subgroup of high-risk patients in whom optimal local therapy is not possible.

Original languageEnglish (US)
Pages (from-to)196-198
Number of pages3
JournalPediatric Blood and Cancer
Volume49
Issue number2
DOIs
StatePublished - Aug 1 2007

Keywords

  • Ewing sarcoma
  • High-dose chemotherapy
  • PNET
  • Tandem autologous stem cell transplantation

ASJC Scopus subject areas

  • Cancer Research
  • Pediatrics, Perinatology, and Child Health
  • Hematology

Fingerprint Dive into the research topics of 'Tandem high-dose chemotherapy with autologous peripheral hematopoietic progenitor cell rescue as consolidation therapy for patients with high-risk Ewing Family Tumors'. Together they form a unique fingerprint.

Cite this